"The chairman of the board has been appointed as the new CEO of Isofol Medical, but we do not anticipate any major strategic overhaul. The ongoing pivotal phase III study AGENT continues to progress according to plan and is preparing to include patients in Japan and Australia. An interim read-out from the study is due in mid-2020. The company reported a Q3 operating loss of SEK46m, fairly in line with our estimate. We reiterate our fair value of SEK18–49/share."
Länk till uppdragsanalys nedan.